



FOR IMMEDIATE RELEASE

Tokyo, September 1, 2025

Notice Regarding Completion of Transfer of Subsidiary Shares

Japan Tobacco Inc. ("JT") (TSE: 2914) announces that the transfer of all common shares of its consolidated subsidiary, TORII PHARMACEUTICAL CO., LTD. ("Torii"), has been completed today. This transfer was conducted through a share buyback of its own share by Torii, in accordance with

the "Notice of Change in Consolidated Subsidiary (Transfer of Subsidiary Shares)" which was

previously announced on May 7, 2025.

###

Japan Tobacco Inc. (JT) is a global company headquartered in Tokyo, Japan. It is listed on the primary section

of the Tokyo Stock Exchange (ticker: 2914.T). JT Group has approximately 53,000 employees and 61 factories

worldwide, operating in three business segments: tobacco, pharmaceutical, and processed food. Within the

tobacco business, the largest segment, products are sold in over 130 markets and its flagship brands include

Winston, Camel, MEVIUS, and LD. The Group is committed to investing in Reduced-Risk Products and markets

its heated tobacco products under its Ploom brand.

Consumers, shareholders, employees, and society are the four stakeholder groups (4S) at the heart of all of JT

Group's activities. Inspired by its "Fulfilling Moments, Enriching Life" purpose, the Group aims to ensure

sustainable and valuable contributions to its stakeholders over the long term. In addition to our three business

segments, this goal is also supported by D-LAB, the JT Group's corporate R&D initiative, set up to search and

create added-value business opportunities. For more information, visit https://www.jt.com/.

Contacts: Yunosuke Miyata, Director

Investor & Media Relations Division

Japan Tobacco Inc.

Tokyo: +81-3-6636-2914

E-mail: jt.media.relations@jt.com

* https://www.jt.com/media/news/2025/pdf/20250507_11.pdf